Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

British Journal of Haematology

Volumn 162, Issue 5, 2013, Pages 587-605

  Kulasekararaj, Austin G ^a,b   Mohamedali, Azim M ^a,b   Mufti, Ghulam J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Genomic sequencing; Molecular pathogenesis; Myelodysplastic syndromes

Indexed keywords

B RAF KINASE; CBL PROTEIN; CD135 ANTIGEN; DNA; DNA METHYLTRANSFERASE 3A; HISTONE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; RNA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1;

BIOGENESIS; CELL ADHESION; CLINICAL PRACTICE; CLONAL EVOLUTION; COHORT ANALYSIS; CYTOGENETICS; DNA BINDING; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HISTONE MODIFICATION; HUMAN; KARYOTYPING; MOLECULAR MECHANICS; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA SPLICING; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME;

GENOMIC SEQUENCING; MOLECULAR PATHOGENESIS; MYELODYSPLASTIC SYNDROMES;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PHENOTYPE;

EID: 84881665644     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12435     Document Type: Review

References (151)

1. Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., Huberman, K., Thomas, S., Dolgalev, I., Heguy, A., Paietta, E., Le Beau, M.M., Beran, M., Tallman, M.S., Ebert, B.L., Kantarjian, H.M., Stone, R.M., Gilliland, D.G., Crispino, J.D. & Levine, R.L. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114, 144-147.
2. Abdel-Wahab, O., Kilpivaara, O., Patel, J., Busque, L. & Levine, R.L. (2010) The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukaemia, 24, 1656-1657.
3. Abdel-Wahab, O., Adli, M., Lafave, L.M., Gao, J., Hricik, T., Shih, A.H., Pandey, S., Patel, J.P., Chung, Y.R., Koche, R., Perna, F., Zhao, X., Taylor, J.E., Park, C.Y., Carroll, M., Melnick, A., Nimer, S.D., Jaffe, J.D., Aifantis, I., Bernstein, B.E. & Levine, R.L. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell, 22, 180-193.
4. Abrahamsson, A.E., Geron, I., Gotlib, J., Dao, K.H., Barroga, C.F., Newton, I.G., Giles, F.J., Durocher, J., Creusot, R.S., Karimi, M., Jones, C., Zehnder, J.L., Keating, A., Negrin, R.S., Weissman, I.L. & Jamieson, C.H. (2009) Glycogen synthase kinase 3beta missplicing contributes to leukaemia stem cell generation. Proceedings of the National Academy of Sciences of the United States of America, 106, 3925-3929.
5. Acquaviva, C., Gelsi-Boyer, V. & Birnbaum, D. (2010) Myelodysplastic syndromes: lost between two states? Leukaemia, 24, 1-5.
6. Bacher, U., Haferlach, T., Kern, W., Haferlach, C. & Schnittger, S. (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukaemia. Haematologica, 92, 744-752.
7. Bains, A., Luthra, R., Medeiros, L.J. & Zuo, Z. (2011) FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukaemia. American Journal of Clinical Pathology, 135, 62-69.
8. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Spensberger, D., de Knegt, Y., Tang, M., Lowenberg, B. & Delwel, R. (2005) Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukaemia. Oncogene, 24, 4129-4137.
9. Barlow, J.L., Drynan, L.F., Hewett, D.R., Holmes, L.R., Lorenzo-Abalde, S., Lane, A.L., Jolin, H.E., Pannell, R., Middleton, A.J., Wong, S.H., Warren, A.J., Wainscoat, J.S., Boultwood, J. & McKenzie, A.N. (2010) A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nature Medicine, 16, 59-66.
10. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine, 364, 2496-2506.
11. Bejar, R., Stevenson, K.E., Caughey, B.A., Abdel-Wahab, O., Steensma, D.P., Galili, N., Raza, A., Kantarjian, H., Levine, R.L., Neuberg, D., Garcia-Manero, G. & Ebert, B.L. (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology, 30, 3376-3382.
12. Belli, C.B., Bengio, R., Aranguren, P.N., Sakamoto, F., Flores, M.G., Watman, N., Nucifora, E., Prates, M.V., Arbelbide, J. & Larripa, I. (2011) Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. American Journal of Hematology, 86, 540-545.
13. Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. (2010) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukaemia. Leukaemia, 24, 1062-1065.
14. Breems, D.A. & Lowenberg, B. (2011) Acute myeloid leukaemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica, 96, 491-493.
15. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukaemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
16. Busque, L., Patel, J.P., Figueroa, M.E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., Hassimi, M., Socci, N., Bhatt, P.K., Gonen, M., Mason, C.E., Melnick, A., Godley, L.A., Brennan, C.W., Abdel-Wahab, O. & Levine, R.L. (2012) Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 44, 1179-1181.
17. Ceesay, M.M., Lea, N.C., Ingram, W., Westwood, N.B., Gaken, J., Mohamedali, A., Cervera, J., Germing, U., Gattermann, N., Giagounidis, A., Garcia-Casado, Z., Sanz, G. & Mufti, G.J. (2006) The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukaemia, 20, 2060-2061.
18. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 23-31.
19. Chen, C.Y., Lin, L.I., Tang, J.L., Ko, B.S., Tsay, W., Chou, W.C., Yao, M., Wu, S.J., Tseng, M.H. & Tien, H.F. (2007) RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology, 139, 405-414.
20. Chen, C.C., Wang, K.Y. & Shen, C.K. (2012) The mammalian de novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine dehydroxymethylases. Journal of Biological Chemistry, 287, 33116-33121.
21. Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2004) Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood, 104, 1474-1481.
22. Christiansen, D.H., Andersen, M.K., Desta, F. & Pedersen-Bjergaard, J. (2005) Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukaemia. Leukaemia, 19, 2232-2240.
23. Cilloni, D., Gottardi, E., Messa, F., Fava, M., Scaravaglio, P., Bertini, M., Girotto, M., Marinone, C., Ferrero, D., Gallamini, A., Levis, A. & Saglio, G. (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 21, 1988-1995.
24. Cloos, P.A., Christensen, J., Agger, K. & Helin, K. (2008) Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes & Development, 22, 1115-1140.
25. Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronne, L., Scourzic, L., Chesnais, V., Guerci-Bresler, A., Slama, B., Beyne-Rauzy, O., Schmidt-Tanguy, A., Stamatoullas-Bastard, A., Dreyfus, F., Prebet, T., de Botton, S., Vey, N., Morgan, M.A., Cross, N.C., Preudhomme, C., Birnbaum, D., Bernard, O.A. & Fontenay, M. (2012) Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 119, 3211-3218.
26. Damm, F., Itzykson, R., Kosmider, O., Droin, N., Renneville, A., Chesnais, V., Gelsi-Boyer, V., de Botton, S., Vey, N., Preudhomme, C., Clavert, A., Delabesse, E., Park, S., Birnbaum, D., Fontenay, M., Bernard, O.A. & Solary, E. (2013) SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukaemia and secondary acute myeloid leukaemias. Leukaemia, 27, 1401-1403.
27. Daubner, G.M., Clery, A., Jayne, S., Stevenin, J. & Allain, F.H. (2012) A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO Journal, 31, 162-174.
28. Daver, N., Strati, P., Jabbour, E., Kadia, T., Luthra, R., Wang, S., Patel, K., Ravandi, F., Cortes, J., Qin Dong, X., Kantarjian, H. & Garcia-Manero, G. (2013) FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukaemia. American Journal of Hematology, 88, 56-59.
29. Deeg, H.J., Scott, B.L., Fang, M., Shulman, H.M., Gyurkocza, B., Myerson, D., Pagel, J.M., Platzbecker, U., Ramakrishnan, A., Radich, J.P., Sandmaier, B.M., Sorror, M., Stirewalt, D.L., Wilson, W.A., Storb, R., Appelbaum, F.R. & Gooley, T. (2012) Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukaemia evolving from MDS. Blood, 120, 1398-1408.
30. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 360, 2289-2301.
31. Dohner, H. & Gaidzik, V.I. (2011) Impact of genetic features on treatment decisions in AML. American Society of Hematology Education Program, 2011, 36-42.
32. Dunbar, A.J., Gondek, L.P., O'Keefe, C.L., Makishima, H., Rataul, M.S., Szpurka, H., Sekeres, M.A., Wang, X.F., McDevitt, M.A. & Maciejewski, J.P. (2008) 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Research, 68, 10349-10357.
33. Edmond, V., Moysan, E., Khochbin, S., Matthias, P., Brambilla, C., Brambilla, E., Gazzeri, S. & Eymin, B. (2011) Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO Journal, 30, 510-523.
34. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H. & Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 42, 722-726.
35. Estey, E.H. (2012) How to manage high-risk acute myeloid leukaemia. Leukaemia, 26, 861-869.
36. Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Lai, J.L., Vanrumbeke, M., Loucheux-Lefebvre, M.H., Bauters, F., Berger, R. & Kerckaert, J.P. (1992) Mutations of the P53 gene in acute myeloid leukaemia. British Journal of Haematology, 80, 178-183.
37. Fisher, C.L., Randazzo, F., Humphries, R.K. & Brock, H.W. (2006) Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family. Gene, 369, 109-118.
38. Fisher, C.L., Pineault, N., Brookes, C., Helgason, C.D., Ohta, H., Bodner, C., Hess, J.L., Humphries, R.K. & Brock, H.W. (2010) Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukaemia. Blood, 115, 38-46.
39. Fitzgibbon, J., Smith, L.L., Raghavan, M., Smith, M.L., Debernardi, S., Skoulakis, S., Lillington, D., Lister, T.A. & Young, B.D. (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukaemias. Cancer Research, 65, 9152-9154.
40. Gaidzik, V.I., Schlenk, R.F., Paschka, P., Kohne, C.-H., Held, G., Habdank, M., Gohlke, J., Mergenthaler, H.-G., Salwender, H.J., Bullinger, L., Dohner, H. & Dohner, K. (2010) TET2 mutations in acute myeloid leukaemia (AML): results on 783 patients treated within the AML HD98A study of the AML Study Group (AMLSG). Blood (ASH Annual Meeting Abstracts), 116, 97.
41. Ganetzky, R.D., Jankowska, A.M., Prince, C., Advani, A., Saunthararajah, Y. & Maciejewski, J.P. (2009) TET2 mutation status is associated with distinct hypermethylation patterns; a marker of epigenetic instability? Blood (ASH Annual Meeting Abstracts), 114, 215.
42. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 145, 788-800.
43. Germing, U., Hildebrandt, B., Pfeilstocker, M., Nosslinger, T., Valent, P., Fonatsch, C., Lubbert, M., Haase, D., Steidl, C., Krieger, O., Stauder, R., Giagounidis, A.A., Strupp, C., Kundgen, A., Mueller, T., Haas, R., Gattermann, N. & Aul, C. (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukaemia, 19, 2223-2231.
44. Gondek, L.P., Tiu, R., O'Keefe, C.L., Sekeres, M.A., Theil, K.S. & Maciejewski, J.P. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood, 111, 1534-1542.
45. Grand, F.H., Hidalgo-Curtis, C.E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., Oscier, D., Hall, A., Brandts, C., Serve, H., Reiter, A., Chase, A.J. & Cross, N.C. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 113, 6182-6192.
46. Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J., Krysiak, K., Harris, C.C., Koboldt, D.C., Larson, D.E., McLellan, M.D., Dooling, D.J., Abbott, R.M., Fulton, R.S., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Grillot, M., Baty, J., Heath, S., Frater, J.L., Nasim, T., Link, D.C., Tomasson, M.H., Westervelt, P., DiPersio, J.F., Mardis, E.R., Ley, T.J., Wilson, R.K. & Walter, M.J. (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 44, 53-57.
47. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
48. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
49. Grossmann, V., Bacher, U., Kohlmann, A., Artusi, V., Klein, H.U., Dugas, M., Schnittger, S., Alpermann, T., Kern, W., Haferlach, T. & Haferlach, C. (2012) EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. British Journal of Haematology, 157, 387-390.
50. Growney, J.D., Shigematsu, H., Li, Z., Lee, B.H., Adelsperger, J., Rowan, R., Curley, D.P., Kutok, J.L., Akashi, K., Williams, I.R., Speck, N.A. & Gilliland, D.G. (2005) Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood, 106, 494-504.
51. Haferlach, C., Bacher, U., Schnittger, S., Alpermann, T., Zenger, M., Kern, W. & Haferlach, T. (2012) ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer, 51, 328-337.
52. Hahn, C.N., Chong, C.E., Carmichael, C.L., Wilkins, E.J., Brautigan, P.J., Li, X.C., Babic, M., Lin, M., Carmagnac, A., Lee, Y.K., Kok, C.H., Gagliardi, L., Friend, K.L., Ekert, P.G., Butcher, C.M., Brown, A.L., Lewis, I.D., To, L.B., Timms, A.E., Storek, J., Moore, S., Altree, M., Escher, R., Bardy, P.G., Suthers, G.K., D'Andrea, R.J., Horwitz, M.S. & Scott, H.S. (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukaemia. Nature Genetics, 43, 1012-1017.
53. Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A. & Inaba, T. (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukaemia with myelodysplasia. Blood, 103, 2316-2324.
54. Heinrichs, S., Kulkarni, R.V., Bueso-Ramos, C.E., Levine, R.L., Loh, M.L., Li, C., Neuberg, D., Kornblau, S.M., Issa, J.P., Gilliland, D.G., Garcia-Manero, G., Kantarjian, H.M., Estey, E.H. & Look, A.T. (2009) Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukaemia, 23, 1605-1613.
55. Hirai, H., Kobayashi, Y., Mano, H., Hagiwara, K., Maru, Y., Omine, M., Mizoguchi, H., Nishida, J. & Takaku, F. (1987) A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature, 327, 430-432.
56. Huh, J., Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Jasek, M., Makishima, H., Jankowska, A.M., Jiang, Y., Verma, A., Theil, K.S., McDevitt, M.A. & Maciejewski, J.P. (2010) Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer, 49, 390-399.
57. Imai, Y., Kurokawa, M., Izutsu, K., Hangaishi, A., Takeuchi, K., Maki, K., Ogawa, S., Chiba, S., Mitani, K. & Hirai, H. (2000) Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood, 96, 3154-3160.
58. Ingram, W., Lea, N.C., Cervera, J., Germing, U., Fenaux, P., Cassinat, B., Kiladjian, J.J., Varkonyi, J., Antunovic, P., Westwood, N.B., Arno, M.J., Mohamedali, A., Gaken, J., Kontou, T., Czepulkowski, B.H., Twine, N.A., Tamaska, J., Csomer, J., Benedek, S., Gattermann, N., Zipperer, E., Giagounidis, A., Garcia-Casado, Z., Sanz, G. & Mufti, G.J. (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukaemia, 20, 1319-1321.
59. Isono, K., Mizutani-Koseki, Y., Komori, T., Schmidt-Zachmann, M.S. & Koseki, H. (2005) Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes & Development, 19, 536-541.
60. Jadersten, M., Saft, L., Pellagatti, A., Gohring, G., Wainscoat, J.S., Boultwood, J., Porwit, A., Schlegelberger, B. & Hellstrom-Lindberg, E. (2009) Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 94, 1762-1766.
61. Jadersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellstrom-Lindberg, E. & Mufti, G.J. (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29, 1971-1979.
62. Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J., O'Keefe, C.L., Ganetzky, R., McDevitt, M.A. & Maciejewski, J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 6403-6410.
63. Jankowska, A.M., Makishima, H., Tiu, R.V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., Hsi, E.D., List, A., Sekeres, M.A., Rao, A., McDevitt, M.A. & Maciejewski, J.P. (2011) Mutational spectrum analysis of chronic myelomonocytic leukaemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 118, 3932-3941.
64. Jason, L.J., Moore, S.C., Lewis, J.D., Lindsey, G. & Ausio, J. (2002) Histone ubiquitination: a tagging tail unfolds? BioEssays, 24, 166-174.
65. Jerez, A., Gondek, L.P., Jankowska, A.M., Makishima, H., Przychodzen, B., Tiu, R.V., O'Keefe, C.L., Mohamedali, A.M., Batista, D., Sekeres, M.A., McDevitt, M.A., Mufti, G.J. & Maciejewski, J.P. (2012) Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. Journal of Clinical Oncology, 30, 1343-1349.
66. Kakazu, N., Taniwaki, M., Horiike, S., Nishida, K., Tatekawa, T., Nagai, M., Takahashi, T., Akaogi, T., Inazawa, J., Ohki, M. & Abe, T. (1999) Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer, 26, 336-345.
67. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J. & Garcia-Manero, G. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer, 113, 1351-1361.
68. Kar, S.A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M., Guinta, K., Tiu, R.V., Przychodzen, B., Sakaguchi, H., Kojima, S., Sekeres, M.A., List, A.F., McDevitt, M.A. & Maciejewski, J.P. (2013) Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukaemia but largely absent in juvenile myelomonocytic leukaemia. Haematologica, 98, 107-113.
69. Kita-Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H. & Taniwaki, M. (2001) International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. British Journal of Haematology, 115, 309-312.
70. Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Liu, X.S., Aravind, L., Agarwal, S., Maciejewski, J.P. & Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839-843.
71. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguie, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, M., Fenaux, P., Mansat-De Mas, V., Delabesse, E., Guardiola, P., Lacombe, C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, D. & Fontenay, M. (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-3291.
72. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779-1790.
73. Kulasekararaj, A.G., Mohamedali, A.M., Smith, A.E., Lea, N.C., Kizilors, A., Abdallah, A., Nasser, E.E., Mian, S.A., Yiu, R., Gaken, J., Pomplun, S., Jiang, J., Gaymes, T.J., Pasipanodya, P., Hayden, J., Ireland, R.M., Lim, Z., Ho, A.Y., Marsh, J.C.W. & Mufti, G.J. (2010) Polycomb complex group gene mutations and their prognostic relevance in 5-Azacitidine treated myelodysplastic syndrome patients. Blood (ASH Annual Meeting Abstracts), 116, 125.
74. Kulasekararaj, A.G., Smith, A.E., Mian, S.A., Mohamedali, A.M., Krishnamurthy, P., Lea, N.C., Gaken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., Pomplun, S., Marsh, J.C. & Mufti, G.J. (2013) TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. British Journal of Haematology, 160, 660-672.
75. Lai, J.L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Lepelley, P., Wattel, E. & Fenaux, P. (1995) Myelodysplastic syndromes and acute myeloid leukaemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukaemia, 9, 370-381.
76. Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G., Raymakers, R.A., Kamping, E.J., Verhoef, G.E., Verburgh, E., Hagemeijer, A., Vandenberghe, P., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics, 41, 838-842.
77. Laricchia-Robbio, L., Premanand, K., Rinaldi, C.R. & Nucifora, G. (2009) EVI1 impairs myelopoiesis by deregulation of PU.1 function. Cancer Research, 69, 1633-1642.
78. Lasho, T.L., Jimma, T., Finke, C.M., Patnaik, M., Hanson, C.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukaemia -free survival. Blood, 120, 4168-4171.
79. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukaemia. New England Journal of Medicine, 363, 2424-2433.
80. Lin, J., Yao, D.M., Qian, J., Chen, Q., Qian, W., Li, Y., Yang, J., Wang, C.Z., Chai, H.Y., Qian, Z., Xiao, G.F. & Xu, W.R. (2011) Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukaemia and myelodysplastic syndrome. PLoS ONE, 6, e26906.
81. Lorenzo, F., Nishii, K., Monma, F., Kuwagata, S., Usui, E. & Shiku, H. (2006) Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukaemia. Leukaemia Research, 30, 1235-1239.
82. Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T. & Downing, J.R. (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukaemia containing the t(10;11)(q22;q23). Leukaemia, 17, 637-641.
83. Maciejewski, J.P. & Mufti, G.J. (2008) Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood, 112, 965-974.
84. Makishima, H., Rataul, M., Gondek, L.P., Huh, J., Cook, J.R., Theil, K.S., Sekeres, M.A., Kuczkowski, E., O'Keefe, C. & Maciejewski, J.P. (2010a) FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leukaemia Research, 34, 447-453.
85. Makishima, H., Jankowska, A.M., Tiu, R.V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M.A., Putnam, P., Sekeres, M.A., Moliterno, A.R., List, A.F., McDevitt, M.A. & Maciejewski, J.P. (2010b) Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukaemia, 24, 1799-1804.
86. Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A.M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M.G., Sekeres, M.A., Padgett, R.A., Tiu, R.V. & Maciejewski, J.P. (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood, 119, 3203-3210.
87. Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M.G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., Strupp, C., Lazzarino, M., Aul, C. & Cazzola, M. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology, 25, 3503-3510.
88. Malcovati, L., Papaemmanuil, E., Bowen, D.T., Boultwood, J., Della Porta, M.G., Pascutto, C., Travaglino, E., Groves, M.J., Godfrey, A.L., Ambaglio, I., Galli, A., Da Via, M.C., Conte, S., Tauro, S., Keenan, N., Hyslop, A., Hinton, J., Mudie, L.J., Wainscoat, J.S., Futreal, P.A., Stratton, M.R., Campbell, P.J., Hellstrom-Lindberg, E. & Cazzola, M. (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 118, 6239-6246.
89. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukaemia genome. New England Journal of Medicine, 361, 1058-1066.
90. Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, B.D. & Reinberg, D. (2008) Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular Cell, 32, 503-518.
91. Masashi, S., Yung, S.L., Suzuki, T., Kato, M., Sakata, M.Y., Kumano, K., Kawamata, N., Takita, J., Mori, H., Kurokawa, M., Chiba, S., Omine, M., Koeffler, H.P. & Ogawa, S. (2008) Genome-wide analysis of MDS/MPD disclosed frequent homozygous C-Cbl mutations tightly associated with 11q-UPD. Blood (ASH Annual Meeting Abstracts), 112, 855.
92. Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., Koeffler, H.P., Kern, W., Haferlach, C. & Schnittger, S. (2012) SRSF2 mutations in 275 cases with chronic myelomonocytic leukaemia (CMML). Blood, 120, 3080-3088.
93. Meggendorfer, M., Bacher, U., Alpermann, T., Haferlach, C., Kern, W., Gambacorti-Passerini, C., Haferlach, T. & Schnittger, S. (2013) SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukaemia, doi: 10.1038/leu.2013.133.
94. Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.Z., Blum, W., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2011) TET2 mutations improve the new European Leukaemia Net risk classification of acute myeloid leukaemia: a Cancer and Leukaemia Group B study. Journal of Clinical Oncology, 29, 1373-1381.
95. Mian, S.A., Smith, A.E., Kulasekararaj, A.G., Kizilors, A., Mohamedali, A.M., Lea, N.C., Mitsopoulos, K., Ford, K., Nasser, E., Seidl, T. & Mufti, G. (2013) Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica, 98, 1058-1066.
96. Mohamedali, A., Gaken, J., Twine, N.A., Ingram, W., Westwood, N., Lea, N.C., Hayden, J., Donaldson, N., Aul, C., Gattermann, N., Giagounidis, A., Germing, U., List, A.F. & Mufti, G.J. (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood, 110, 3365-3373.
97. Mohamedali, A.M., Smith, A.E., Gaken, J., Lea, N.C., Mian, S.A., Westwood, N.B., Strupp, C., Gattermann, N., Germing, U. & Mufti, G.J. (2009) Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. Journal of Clinical Oncology, 27, 4002-4006.
98. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S.D., Melnick, A., Godley, L.A., Aifantis, I. & Levine, R.L. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20, 11-24.
99. Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, F., Yap, D., Humphries, R.K., Griffith, O.L., Shah, S., Zhu, H., Kimbara, M., Shashkin, P., Charlot, J.F., Tcherpakov, M., Corbett, R., Tam, A., Varhol, R., Smailus, D., Moksa, M., Zhao, Y., Delaney, A., Qian, H., Birol, I., Schein, J., Moore, R., Holt, R., Horsman, D.E., Connors, J.M., Jones, S., Aparicio, S., Hirst, M., Gascoyne, R.D. & Marra, M.A. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics, 42, 181-185.
100. Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446, 758-764.
101. Nerlov, C., Querfurth, E., Kulessa, H. & Graf, T. (2000) GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood, 95, 2543-2551.
102. Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics, 42, 665-667.
103. Ogawa, S., Sanada, M., Shih, L.Y., Suzuki, T., Otsu, M., Nakauchi, H. & Koeffler, H.P. (2010) Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle, 9, 1051-1056.
104. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R. & Campbell, P.J. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New England Journal of Medicine, 365, 1384-1395.
105. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukaemia and confer adverse prognosis in cytogenetically normal acute myeloid leukaemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
106. Pastor, W.A., Pape, U.J., Huang, Y., Henderson, H.R., Lister, R., Ko, M., McLoughlin, E.M., Brudno, Y., Mahapatra, S., Kapranov, P., Tahiliani, M., Daley, G.Q., Liu, X.S., Ecker, J.R., Milos, P.M., Agarwal, S. & Rao, A. (2011) Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature, 473, 394-397.
107. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukaemia. New England Journal of Medicine, 366, 1079-1089.
108. Patmasiriwat, P., Fraizer, G., Kantarjian, H. & Saunders, G.F. (1999) WT1 and GATA1 expression in myelodysplastic syndrome and acute leukaemia. Leukaemia, 13, 891-900.
109. Patnaik, M.M., Hanson, C.A., Hodnefield, J.M., Knudson, R., Van Dyke, D.L. & Tefferi, A. (2011) Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukaemia, 25, 266-270.
110. Patnaik, M.M., Hanson, C.A., Hodnefield, J.M., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012a) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukaemia, 26, 101-105.
111. Patnaik, M.M., Lasho, T.L., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Garcia-Manero, G., Steensma, D.P., Pardanani, A., Hanson, C.A. & Tefferi, A. (2012b) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 119, 569-572.
112. Piazza, R., Valletta, S., Winkelmann, N., Redaelli, S., Spinelli, R., Pirola, A., Antolini, L., Mologni, L., Donadoni, C., Papaemmanuil, E., Schnittger, S., Kim, D.W., Boultwood, J., Rossi, F., Gaipa, G., De Martini, G.P., di Celle, P.F., Jang, H.G., Fantin, V., Bignell, G.R., Magistroni, V., Haferlach, T., Pogliani, E.M., Campbell, P.J., Chase, A.J., Tapper, W.J., Cross, N.C. & Gambacorti-Passerini, C. (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukaemia. Nature Genetics, 45, 18-24.
113. Raghavan, M., Lillington, D.M., Skoulakis, S., Debernardi, S., Chaplin, T., Foot, N.J., Lister, T.A. & Young, B.D. (2005) Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukaemias. Cancer Research, 65, 375-378.
114. Raghavan, M., Smith, L.-L., Lillington, D.M., Chaplin, T., Kakkas, I., Molloy, G., Chelala, C., Cazier, J.-B., Cavenagh, J.D., Fitzgibbon, J., Lister, T.A. & Young, B.D. (2008) Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid Leukaemia. Blood, 112, 814-821.
115. Raza, S., TaherNazerHussain, F., Patnaik, M., Knudson, R., Van Dyke, D. & Tefferi, A. (2011) Autosomal monosomies among 24, 262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. American Journal of Hematology, 86, 353-356.
116. Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foa, R., Dalla-Favera, R. & Gaidano, G. (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukaemia: association with progression and fludarabine-refractoriness. Blood, 118, 6904-6908.
117. Roumier, C., Fenaux, P., Lafage, M., Imbert, M., Eclache, V. & Preudhomme, C. (2003) New mechanisms of AML1 gene alteration in hematological malignancies. Leukaemia, 17, 9-16.
118. Rowley, J.D. (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
119. Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Valent, P., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Faderl, S., Pierce, S., Le Beau, M.M., Bennett, J.M., Greenberg, P., Germing, U. & Haase, D. (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukaemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30, 820-829.
120. Scheuermann, J.C., de Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., McGinty, R.K., Fraterman, S., Wilm, M., Muir, T.W. & Muller, J. (2010) Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature, 465, 243-247.
121. Score, J., Hidalgo-Curtis, C., Jones, A.V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Dohner, K., Chase, A. & Cross, N.C. (2012) Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood, 119, 1208-1213.
122. Smith, M.L., Cavenagh, J.D., Lister, T.A. & Fitzgibbon, J. (2004) Mutation of CEBPA in familial acute myeloid leukaemia. New England Journal of Medicine, 351, 2403-2407.
123. Smith, A.E., Mohamedali, A.M., Kulasekararaj, A., Lim, Z., Gaken, J., Lea, N.C., Przychodzen, B., Mian, S.A., Nasser, E.E., Shooter, C., Westwood, N.B., Strupp, C., Gattermann, N., Maciejewski, J.P., Germing, U. & Mufti, G.J. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 116, 3923-3932.
124. Song, W.J., Sullivan, M.G., Legare, R.D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I.C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A.M., Speck, N.A., Bushweller, J.H., Li, F.P., Gardiner, K., Poncz, M., Maris, J.M. & Gilliland, D.G. (1999) Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics, 23, 166-175.
125. Streubel, B., Valent, P., Lechner, K. & Fonatsch, C. (2001) Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukaemia and a constitutional ring chromosome 21. Cancer Genetics and Cytogenetics, 124, 42-46.
126. Szpurka, H., Jankowska, A.M., Ng, K.P., Clevenger, J.R., Saunthararajah, Y. & Maciejewski, J.P. (2009) Involvement of TET2 in regulation of epigenetic silencing in MDS and related myeloid malignancies. Blood (ASH Annual Meeting Abstracts), 114, 2908.
127. Szpurka, H., Jankowska, A.M., Makishima, H., Bodo, J., Bejanyan, N., Hsi, E.D., Sekeres, M.A. & Maciejewski, J.P. (2010) Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leukaemia Research, 34, 969-973.
128. Tahiliani, M., Koh, K.P., Shen, Y.H., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L. & Rao, A. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324, 930-935.
129. Tamaki, H., Ogawa, H., Ohyashiki, K., Ohyashiki, J.H., Iwama, H., Inoue, K., Soma, T., Oka, Y., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E.H., Kawakami, M., Fuchigami, K., Tomonaga, M., Toyama, K., Aozasa, K., Kishimoto, T. & Sugiyama, H. (1999) The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukaemia, 13, 393-399.
130. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. & Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukaemia (AML). Blood, 107, 4011-4020.
131. Thol, F., Weissinger, E.M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.K., Schlegelberger, B., Ganser, A. & Heuser, M. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica, 95, 1668-1674.
132. Thol, F., Winschel, C., Ludeking, A., Yun, H., Friesen, I., Damm, F., Wagner, K., Krauter, J., Heuser, M. & Ganser, A. (2011) Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica, 96, 1870-1873.
133. Thol, F., Kade, S., Schlarmann, C., Loffeld, P., Morgan, M., Krauter, J., Wlodarski, M.W., Kolking, B., Wichmann, M., Gorlich, K., Gohring, G., Bug, G., Ottmann, O., Niemeyer, C.M., Hofmann, W.K., Schlegelberger, B., Ganser, A. & Heuser, M. (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, 119, 3578-3584.
134. Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Huh, J., Sekeres, M.A., Elson, P., McDevitt, M.A., Wang, X.F., Levis, M.J., Karp, J.E., Advani, A.S. & Maciejewski, J.P. (2009) New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukaemia. Journal of Clinical Oncology, 27, 5219-5226.
135. Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Elson, P., Huh, J., Mohamedali, A., Kulasekararaj, A., Advani, A.S., Paquette, R., List, A.F., Sekeres, M.A., McDevitt, M.A., Mufti, G.J. & Maciejewski, J.P. (2011) Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood, 117, 4552-4560.
136. Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., Bollen, M., Esteller, M., Di Croce, L., de Launoit, Y. & Fuks, F. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 439, 871-874.
137. Visconte, V., Makishima, H., Jankowska, A., Szpurka, H., Traina, F., Jerez, A., O'Keefe, C., Rogers, H.J., Sekeres, M.A., Maciejewski, J.P. & Tiu, R.V. (2012) SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukaemia, 26, 542-545.
138. Walker, B.A., Leone, P.E., Jenner, M.W., Li, C., Gonzalez, D., Johnson, D.C., Ross, F.M., Davies, F.E. & Morgan, G.J. (2006) Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood, 108, 1733-1743.
139. Wall, M., Rayeroux, K.C., MacKinnon, R.N., Zordan, A. & Campbell, L.J. (2012) ETV6 deletion is a common additional abnormality in patients with myelodysplastic syndromes or acute myeloid leukaemia and monosomy 7. Haematologica, 97, 1933-1936.
140. Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Kandoth, C., Baty, J., Westervelt, P., DiPersio, J.F., Mardis, E.R., Wilson, R.K., Ley, T.J. & Graubert, T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukaemia, 25, 1153-1158.
141. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., Fulton, R., Magrini, V., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Fan, X., Grillot, M., Witowski, S., Heath, S., Frater, J.L., Eades, W., Tomasson, M., Westervelt, P., DiPersio, J.F., Link, D.C., Mardis, E.R., Ley, T.J., Wilson, R.K. & Graubert, T.A. (2012) Clonal architecture of secondary acute myeloid leukaemia. New England Journal of Medicine, 366, 1090-1098.
142. Wang, L., Lawrence, M.S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D.S., Zhang, L., Zhang, W., Vartanov, A.R., Fernandes, S.M., Goldstein, N.R., Folco, E.G., Cibulskis, K., Tesar, B., Sievers, Q.L., Shefler, E., Gabriel, S., Hacohen, N., Reed, R., Meyerson, M., Golub, T.R., Lander, E.S., Neuberg, D., Brown, J.R., Getz, G. & Wu, C.J. (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukaemia. New England Journal of Medicine, 365, 2497-2506.
143. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukaemia -associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-234.
144. Welch, J.S., Ley, T.J., Link, D.C., Miller, C.A., Larson, D.E., Koboldt, D.C., Wartman, L.D., Lamprecht, T.L., Liu, F., Xia, J., Kandoth, C., Fulton, R.S., McLellan, M.D., Dooling, D.J., Wallis, J.W., Chen, K., Harris, C.C., Schmidt, H.K., Kalicki-Veizer, J.M., Lu, C., Zhang, Q., Lin, L., O' Laughlin, M.D., McMichael, J.F., Delehaunty, K.D., Fulton, L.A., Magrini, V.J., McGrath, S.D., Demeter, R.T., Vickery, T.L., Hundal, J., Cook, L.L., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T.N., Walker, J.R., Watson, M.A., Heath, S.E., Shannon, W.D., Varghese, N., Nagarajan, R., Payton, J.E., Baty, J.D., Kulkarni, S., Klco, J.M., Tomasson, M.H., Westervelt, P., Walter, M.J., Graubert, T.A., DiPersio, J.F., Ding, L., Mardis, E.R. & Wilson, R.K. (2012) The origin and evolution of mutations in acute myeloid leukaemia. Cell, 150, 264-278.
145. Wu, S.J., Kuo, Y.Y., Hou, H.A., Li, L.Y., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Liu, C.W., Lin, C.T., Chen, C.Y., Chou, W.C., Yao, M., Huang, S.Y., Ko, B.S., Tang, J.L., Tsay, W. & Tien, H.F. (2012) The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 120, 3106-3111.
146. Xiao, R., Sun, Y., Ding, J.H., Lin, S., Rose, D.W., Rosenfeld, M.G., Fu, X.D. & Li, X. (2007) Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Molecular and Cellular Biology, 27, 5393-5402.
147. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., Liu, L.X., Jiang, W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M. & Xiong, Y. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 17-30.
148. Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., Liang, W.X., Mi, J.Q., Song, H.D., Li, K.Q., Chen, Z. & Chen, S.J. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukaemia. Nature Genetics, 43, 309-315.
149. Yap, D.B., Chu, J., Berg, T., Schapira, M., Cheng, S.W., Moradian, A., Morin, R.D., Mungall, A.J., Meissner, B., Boyle, M., Marquez, V.E., Marra, M.A., Gascoyne, R.D., Humphries, R.K., Arrowsmith, C.H., Morin, G.B. & Aparicio, S.A. (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood, 117, 2451-2459.
150. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.
151. Zhang, Y., Zhang, M., Yang, L. & Xiao, Z. (2007) NPM1 mutations in myelodysplastic syndromes and acute myeloid leukaemia with normal karyotype. Leukaemia Research, 31, 109-111.